ArticlePubMed 19
These include model phenotyping studies and the characterization of several MASH-targeted drug classes, such as GLP1R agonists (e.g., semaglutide), THR- receptor agonists (e.g., resmetirom), PPAR agonists (e.g., lanifibranor), FGF21 analogues (e.g., efruxifermin), as well as various long-acting dual GLP1R-GIPR agonists (e.g., tirzepatide) and GLP1R-GCGR agonists (e.g., survodutide)
A., Freitas, T
Side Effects and Safety Monitoring The most common adverse effects in clinical trials were gastrointestinal: nausea (15.8%, 20.3%), diarrhea (8.5%, 8.8%), and vomiting (5.0%, 9.2%) [1]
El glutatin no presenta peligro Actualmente, los estudios cientficos no han demostrado ningn peligro respecto a la ingesta de glutatin